Catheter Precision Divests Non-Core Assets to Focus on Electrophysiology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy VTAK?
Source: Benzinga
- Strategic Divestiture: Catheter Precision announced the sale of its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer, aiming to enhance capital efficiency and focus on its high-growth electrophysiology platform.
- Transaction Highlights: The deal includes a $15,000 upfront cash payment, a 5% equity stake in the acquiring company, and a ten-year royalty agreement on net sales, which is expected to accelerate execution across its electrophysiology product portfolio.
- Stock Price Trend: VTAK shares are currently priced at $1.61, trading 21.1% below the 20-day simple moving average and 31.7% below the 100-day SMA, indicating a bearish short-term trend.
- Market Performance: Over the past 12 months, VTAK shares have decreased by 75.82%, nearing their 52-week low of $1.13, with a current RSI of 44.39 indicating neutral territory, while the MACD at -0.1249 suggests ongoing bearish pressure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTAK
About VTAK
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catheter Precision Divests Non-Core Assets to Focus on Electrophysiology
- Strategic Divestiture: Catheter Precision announced the sale of its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer, aiming to enhance capital efficiency and focus on its high-growth electrophysiology platform.
- Transaction Highlights: The deal includes a $15,000 upfront cash payment, a 5% equity stake in the acquiring company, and a ten-year royalty agreement on net sales, which is expected to accelerate execution across its electrophysiology product portfolio.
- Stock Price Trend: VTAK shares are currently priced at $1.61, trading 21.1% below the 20-day simple moving average and 31.7% below the 100-day SMA, indicating a bearish short-term trend.
- Market Performance: Over the past 12 months, VTAK shares have decreased by 75.82%, nearing their 52-week low of $1.13, with a current RSI of 44.39 indicating neutral territory, while the MACD at -0.1249 suggests ongoing bearish pressure.
See More
Creatd Forms Strategic Partnership with VTAK for Fly Flyte
- Investor Network Expansion: Creatd successfully adds a 20% equity investment from NYSE-listed VTAK into its subsidiary Fly Flyte, enhancing Fly Flyte's capital base and market competitiveness.
- Portfolio Strategy Advancement: Creatd is actively engaging in multiple acquisition discussions to advance its portfolio strategy, aiming to support growth and transitions for small-cap companies through integrated services.
- Aviation Innovation Transformation: Fly Flyte enhances accessibility and convenience by providing AI-driven regional aviation services, leveraging certified aircraft and established routes to generate real-time revenue, showcasing strong market potential.
- Long-term Value Creation: This transaction not only maintains Fly Flyte's operational independence but also aligns with Creatd's long-term value creation strategy, demonstrating the company's commitment to sustainable growth in technology-driven sectors.
See More
Creatd Forms Strategic Partnership with VTAK for Fly Flyte
- Investor Network Expansion: Creatd has successfully introduced a 20% equity investment in its subsidiary Fly Flyte through a partnership with NYSE-listed VTAK, enhancing Fly Flyte's capital base and providing financial support for future growth.
- Portfolio Strategy Advancement: Creatd is actively engaged in multiple acquisition discussions, aiming to build a service foundation that supports growth-driven small-cap companies by integrating capabilities from banking, investing, and advisory services, thereby enhancing its market competitiveness.
- Aviation Innovation Transformation: Fly Flyte leverages AI technology to provide regional aviation services designed to increase accessibility and convenience, creating real-time revenue through established routes and scalable infrastructure while positioning for long-term expansion.
- Operational Independence Assurance: This investment not only provides financial backing for Fly Flyte but also ensures its operational independence and strategic focus, aligning with Creatd's emphasis on the long-term value creation potential of technology-enabled subsidiaries.
See More
VTAK Terminates ATM Equity Offering Program to Strengthen Balance Sheet
- Termination of Financing Plan: Catheter Precision has announced the termination of its ATM equity offering program, with no future equity lines of credit or forward-priced agreements anticipated, thereby eliminating financing burdens and enhancing financial stability.
- Strategic Financing Completed: The company has secured up to $36.5 million in a financing transaction with institutional investors aimed at supporting accelerated growth, significantly strengthening its capital structure and liquidity.
- Debt Structure Optimization: The company has converted short-term notes into long-term debt, extending maturities to two and three years, while approximately $9 million in short and long-term liabilities are being converted into equity, further improving its financial position.
- Strengthened Growth Strategy: This strategic investment provides the company with financial flexibility to advance key growth initiatives, expand market presence, and enhance execution capabilities, thereby creating long-term value for shareholders.
See More
Catheter Precision Implements LockeT at Ireland's Largest EP Center
- Global Expansion Milestone: Catheter Precision successfully implements LockeT at Mater Private Hospital in Ireland, marking a significant advancement in the company's global expansion strategy while enhancing procedural safety and efficiency in cardiac care.
- Key Partnership: As Ireland's largest electrophysiology center performing over 1,000 procedures annually, Mater Private's adoption of LockeT will significantly enhance innovation in arrhythmia treatment.
- Rapid Training and Adoption: The chief nurse trained 52 staff members in just two days, showcasing LockeT's intuitive design and operational efficiency, which ensures swift adoption of the device.
- Market Validation: The European Sales Manager highlighted that Mater Private's multi-year commitment to LockeT validates the technology's value and strengthens Catheter Precision's position in the global electrophysiology market.
See More
Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
See More
Catheter Precision Divests Non-Core Assets to Focus on Electrophysiology
- Strategic Divestiture: Catheter Precision announced the sale of its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer, aiming to enhance capital efficiency and focus on its high-growth electrophysiology platform.
- Transaction Highlights: The deal includes a $15,000 upfront cash payment, a 5% equity stake in the acquiring company, and a ten-year royalty agreement on net sales, which is expected to accelerate execution across its electrophysiology product portfolio.
- Stock Price Trend: VTAK shares are currently priced at $1.61, trading 21.1% below the 20-day simple moving average and 31.7% below the 100-day SMA, indicating a bearish short-term trend.
- Market Performance: Over the past 12 months, VTAK shares have decreased by 75.82%, nearing their 52-week low of $1.13, with a current RSI of 44.39 indicating neutral territory, while the MACD at -0.1249 suggests ongoing bearish pressure.
See More
Creatd Forms Strategic Partnership with VTAK for Fly Flyte
- Investor Network Expansion: Creatd successfully adds a 20% equity investment from NYSE-listed VTAK into its subsidiary Fly Flyte, enhancing Fly Flyte's capital base and market competitiveness.
- Portfolio Strategy Advancement: Creatd is actively engaging in multiple acquisition discussions to advance its portfolio strategy, aiming to support growth and transitions for small-cap companies through integrated services.
- Aviation Innovation Transformation: Fly Flyte enhances accessibility and convenience by providing AI-driven regional aviation services, leveraging certified aircraft and established routes to generate real-time revenue, showcasing strong market potential.
- Long-term Value Creation: This transaction not only maintains Fly Flyte's operational independence but also aligns with Creatd's long-term value creation strategy, demonstrating the company's commitment to sustainable growth in technology-driven sectors.
See More
Creatd Forms Strategic Partnership with VTAK for Fly Flyte
- Investor Network Expansion: Creatd has successfully introduced a 20% equity investment in its subsidiary Fly Flyte through a partnership with NYSE-listed VTAK, enhancing Fly Flyte's capital base and providing financial support for future growth.
- Portfolio Strategy Advancement: Creatd is actively engaged in multiple acquisition discussions, aiming to build a service foundation that supports growth-driven small-cap companies by integrating capabilities from banking, investing, and advisory services, thereby enhancing its market competitiveness.
- Aviation Innovation Transformation: Fly Flyte leverages AI technology to provide regional aviation services designed to increase accessibility and convenience, creating real-time revenue through established routes and scalable infrastructure while positioning for long-term expansion.
- Operational Independence Assurance: This investment not only provides financial backing for Fly Flyte but also ensures its operational independence and strategic focus, aligning with Creatd's emphasis on the long-term value creation potential of technology-enabled subsidiaries.
See More
VTAK Terminates ATM Equity Offering Program to Strengthen Balance Sheet
- Termination of Financing Plan: Catheter Precision has announced the termination of its ATM equity offering program, with no future equity lines of credit or forward-priced agreements anticipated, thereby eliminating financing burdens and enhancing financial stability.
- Strategic Financing Completed: The company has secured up to $36.5 million in a financing transaction with institutional investors aimed at supporting accelerated growth, significantly strengthening its capital structure and liquidity.
- Debt Structure Optimization: The company has converted short-term notes into long-term debt, extending maturities to two and three years, while approximately $9 million in short and long-term liabilities are being converted into equity, further improving its financial position.
- Strengthened Growth Strategy: This strategic investment provides the company with financial flexibility to advance key growth initiatives, expand market presence, and enhance execution capabilities, thereby creating long-term value for shareholders.
See More
Catheter Precision Implements LockeT at Ireland's Largest EP Center
- Global Expansion Milestone: Catheter Precision successfully implements LockeT at Mater Private Hospital in Ireland, marking a significant advancement in the company's global expansion strategy while enhancing procedural safety and efficiency in cardiac care.
- Key Partnership: As Ireland's largest electrophysiology center performing over 1,000 procedures annually, Mater Private's adoption of LockeT will significantly enhance innovation in arrhythmia treatment.
- Rapid Training and Adoption: The chief nurse trained 52 staff members in just two days, showcasing LockeT's intuitive design and operational efficiency, which ensures swift adoption of the device.
- Market Validation: The European Sales Manager highlighted that Mater Private's multi-year commitment to LockeT validates the technology's value and strengthens Catheter Precision's position in the global electrophysiology market.
See More
Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
See More
